Table 2 Association of EFS and survival surrogates for patients undergoing treatment with neoadjuvant PD-1 blockade plus chemotherapy
Path-evaluable population | ||||
|---|---|---|---|---|
Survival surrogate | No. | HR (EFS) | 95% CI | p-value |
Radiographic response by RECIST 1.1 : responders versus non-responders | 57 (responders) 36 (non-responders) | 2.4 | 0.66–8.8 | 0.183 |
Pathological response: pCR versus non-pCR | 35 (pCR) 64 (non-pCR) | 0.35 | 0.078–1.6 | 0.175 |
Pathological response: MPR versus non-MPR | 53 (MPR) 46 (non-MPR) | 0.36 | 0.11–1.8 | 0.092 |
CD8+ nTIL density: High CD8+ nTIL density versus Low CD8+ nTIL density | 49 (High) 50 (Low) | 0.081 | 0.01–0.62 | 0.016* |
CD3+ nTIL density: High CD3+ nTIL density versus Low CD3+ nTIL density | 49 (High) 50 (Low) | 0.31 | 0.086–1.1 | 0.077 |
